Recent study reveals nirmatrelvir treatment during acute COVID-19 does not lower the risk of post-acute COVID-19 symptoms, nor is it associated with symptomatic rebound.
Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals
- Post author:
- Post published:January 8, 2024
- Post category:uncategorized